{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=34", "query": { "intervention": "placebo oral capsules", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2673, "total_pages": 268, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T15:01:59.529Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00893269", "title": "The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Marijuana Dependence" ], "interventions": [ { "name": "eszopiclone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "ramelteon", "type": "DRUG" }, { "name": "zolpidem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2008-10", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2013-12-05", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00893269" }, { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" }, { "nct_id": "NCT00959751", "title": "Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine Without Aura" ], "interventions": [ { "name": "NXN-188", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeurAxon Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 195, "start_date": "2009-07", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-07-23", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 4, "location_summary": "St. Petersburg, Florida • Atlanta, Georgia • Mount Vernon, New York + 1 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Mount Vernon", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959751" }, { "nct_id": "NCT06638502", "title": "Safety of HRX215 in Patients After Minor and Major Liver Resection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Resection", "Colorectal Carcinoma Liver Metastases" ], "interventions": [ { "name": "HRX215 capsules", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HepaRegeniX GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2025-05-06", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06638502" }, { "nct_id": "NCT05156281", "title": "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Remibrutinib", "type": "DRUG" }, { "name": "Teriflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1007, "start_date": "2021-12-13", "completion_date": "2030-10-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hanford", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156281" }, { "nct_id": "NCT03980730", "title": "Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Azeliragon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "vTv Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 43, "start_date": "2019-06-27", "completion_date": "2021-01-29", "has_results": true, "last_update_posted_date": "2022-01-21", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 27, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03980730" }, { "nct_id": "NCT07660107", "title": "Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Safety", "Tolerability" ], "interventions": [ { "name": "Heat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo (microcrystalline cellulose)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Kioga Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2025-07-07", "completion_date": "2025-07-15", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 1, "location_summary": "Boulder, Colorado", "locations": [ { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07660107" }, { "nct_id": "NCT04625595", "title": "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type1 Diabetes" ], "interventions": [ { "name": "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" }, { "name": "700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" }, { "name": "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" }, { "name": "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunomolecular Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2020-11-09", "completion_date": "2021-07-31", "has_results": false, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 3, "location_summary": "Chula Vista, California • Aurora, Colorado • Renton, Washington", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04625595" }, { "nct_id": "NCT04768569", "title": "Noise-Induced Hearing Loss-Acute Exposure Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hearing Loss, Noise-Induced" ], "interventions": [ { "name": "Zonisamide 100Mg Cap", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-10-04", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04768569" }, { "nct_id": "NCT02372253", "title": "Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Verapamil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 32, "start_date": "2015-02", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-17T15:01:59.529Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02372253" } ] }